Sunday, June 05, 2022 7:25:31 PM
• The EX-CELL® CD Insect Cell Medium has been formulated to optimize the growth, viability and productivity of the
Sf-rhabdovirus-negative (Sf-RVN®) Insect Cell Line. Combined, these two products form the Sf-RVN® Platform and provide
a high performant rhabdovirus-free BEVS alternative to produce recombinant proteins, Virus-Like Particles (VLP) for viral
vaccines, and Adeno-Associated Viruses (AAV) to treat genetic diseases.
• In this study we demonstrated that the EX-CELL® CD Insect Cell Medium out-performs all media tested, including the not
chemically defined media, for the growth of both Sf-RVN® and Sf9 cells.
• For the Sf-RVN® Insect Cell Line, our data shown that the EX-CELL® CD Insect Cell Medium enables the second-best production
after the EX-CELL® 420 Serum-Free Medium while improving lot-to-lot consistency of the medium, which is a common issue
with hydrolysate containing formulations.
• By comparing the productivity of the two Sf9 cells, we demonstrated that the Sf-RVN® cells had a higher SEAP productivity
than the Sf9 cells, especially when cultivated with companion EX-CELL® CD Insect Cell Medium
https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/marketing/global/documents/261/022/poster-ex-cell-cd-insect-cell-medium-ms.pdf
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM